South Korea · Delayed Price · Currency is KRW LabGenomics Statistics
Total Valuation
LabGenomics has a market cap or net worth of KRW 37.12 billion. The enterprise value is 62.96 billion.
| Market Cap | 37.12B |
| Enterprise Value | 62.96B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LabGenomics has 74.24 million shares outstanding. The number of shares has increased by 0.46% in one year.
| Current Share Class | 74.24M |
| Shares Outstanding | 74.24M |
| Shares Change (YoY) | +0.46% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 5.43% |
| Float | 58.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.48 |
| PB Ratio | 0.25 |
| P/TBV Ratio | 0.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.00, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.00 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.34 |
| Interest Coverage | -6.44 |
Financial Efficiency
Return on equity (ROE) is -30.59% and return on invested capital (ROIC) is -35.14%.
| Return on Equity (ROE) | -30.59% |
| Return on Assets (ROA) | -10.08% |
| Return on Invested Capital (ROIC) | -35.14% |
| Return on Capital Employed (ROCE) | -22.68% |
| Weighted Average Cost of Capital (WACC) | 6.90% |
| Revenue Per Employee | 739.43M |
| Profits Per Employee | -491.38M |
| Employee Count | 105 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 17.35 |
Taxes
In the past 12 months, LabGenomics has paid 8.07 billion in taxes.
| Income Tax | 8.07B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.02% in the last 52 weeks. The beta is 0.19, so LabGenomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | -78.02% |
| 50-Day Moving Average | 682.92 |
| 200-Day Moving Average | 1,370.51 |
| Relative Strength Index (RSI) | 34.72 |
| Average Volume (20 Days) | 2,805,566 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LabGenomics had revenue of KRW 77.64 billion and -51.60 billion in losses. Loss per share was -696.05.
| Revenue | 77.64B |
| Gross Profit | 25.46B |
| Operating Income | -40.08B |
| Pretax Income | -43.52B |
| Net Income | -51.60B |
| EBITDA | -31.55B |
| EBIT | -40.08B |
| Loss Per Share | -696.05 |
Balance Sheet
The company has 36.72 billion in cash and 62.56 billion in debt, with a net cash position of -25.84 billion or -348.11 per share.
| Cash & Cash Equivalents | 36.72B |
| Total Debt | 62.56B |
| Net Cash | -25.84B |
| Net Cash Per Share | -348.11 |
| Equity (Book Value) | 147.96B |
| Book Value Per Share | 1,982.33 |
| Working Capital | -100.42M |
Cash Flow
In the last 12 months, operating cash flow was -25.50 billion and capital expenditures -1.29 billion, giving a free cash flow of -26.79 billion.
| Operating Cash Flow | -25.50B |
| Capital Expenditures | -1.29B |
| Depreciation & Amortization | 9.32B |
| Net Borrowing | 2.20B |
| Free Cash Flow | -26.79B |
| FCF Per Share | -360.84 |
Margins
Gross margin is 32.80%, with operating and profit margins of -51.62% and -66.45%.
| Gross Margin | 32.80% |
| Operating Margin | -51.62% |
| Pretax Margin | -56.06% |
| Profit Margin | -66.45% |
| EBITDA Margin | -40.63% |
| EBIT Margin | -51.62% |
| FCF Margin | n/a |
Dividends & Yields
LabGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.46% |
| Shareholder Yield | -0.46% |
| Earnings Yield | -139.00% |
| FCF Yield | -72.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 7, 2023. It was a forward split with a ratio of 2.
| Last Split Date | Aug 7, 2023 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
LabGenomics has an Altman Z-Score of 1.19 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.19 |
| Piotroski F-Score | 2 |